AskEdgar

1.1K posts

AskEdgar

AskEdgar

@AskEdgarIO

The new standard for trading research, now autonomous. Building AI agents on SEC filings and proprietary data.

AI Katılım Ekim 2023
386 Takip Edilen3.6K Takipçiler
Kelan
Kelan@kelanfar·
Added a little bit of fuel to the fire on $SNDK today, feels good to not fight these monster rallies in semis. I am also long $AMD and $MU in a long-term investments account, no clue when to sell those or just to leave the positions.
Kelan tweet media
English
4
2
71
3.7K
AskEdgar
AskEdgar@AskEdgarIO·
Premarket Movers: $PHOE (+91.76% | $36.55): Continuing its massive momentum driven by the recently announced transformational $1 billion acquisition of clinical-stage biotech ACEA Pharma. $AIIO (+76.51% | $1.04): Rallying on the definitive agreement to acquire data processing firm Neurovia AI Limited for $100 million in stock to bolster its physical AI infrastructure. $INOD (+51.32% | $69.13): Skyrocketing after reporting blowout Q1 earnings with a 54% revenue increase and raising full-year guidance fueled by $51 million in new Big Tech AI contracts. $GDC (+48.74% | $0.2246): Extending gains as traders anticipate developments from the newly formed special committee evaluating a massive $10.75 per share going-private buyout proposal. $AEHL (+47.09% | $0.75): Spiking after announcing realized gains from its Bitcoin treasury strategy today and authorizing a new share repurchase program. $TRAW (+30.59% | $2.23): Running on today's announcement of an emergency initiative to develop clinical treatments for the highly fatal Hantavirus. $AKAM (+24.27% | $145.53): Gaining heavily after securing a landmark $1.8 billion, seven-year cloud infrastructure commitment from a leading AI frontier model provider. $IRE (+23.99% | $39.60): Moving in tandem with Iris Energy's massive breakout following its newly announced 5 GW AI infrastructure partnership with NVIDIA. $FLNC (+23.30% | $23.40): Breaking out after reporting a record $5.6 billion backlog and securing master supply agreements with two major hyperscalers for AI data center energy storage.
English
0
0
1
514
AskEdgar
AskEdgar@AskEdgarIO·
new in our docs: how to build a dilution risk monitor across your watchlist. four endpoints stitched together: - dilution-rating for the composite score - registrations for active shelf capacity - nasdaq-compliance for delisting pressure - float-outstanding for shelf-to-float context full code, alert conditions, cost math. ~5 mins to read.
English
0
0
1
555
AskEdgar
AskEdgar@AskEdgarIO·
Premarket Movers $GLE (+99.14% | $0.7184): Surged after announcing a non-binding MOU with Angkasa-X to explore integrating satellite networks, data infrastructure, and blockchain technology for AI applications. $AGL (+50.77% | $41.99): Rallied on strong Q1 earnings that featured a 162% surge in adjusted EBITDA and raised full-year guidance, validating the company's profitability-focused turnaround strategy. $ATRA (+44.90% | $7.48): Spiked after announcing a positive FDA update confirming that a single-arm study with a historical control can support the resubmission of its tab-cel Biologics License Application. $FLNC (+35.55% | $18.40): Jumped after reporting a record $5.6 billion backlog and announcing master supply agreements with two major hyperscalers for AI data center battery storage. $OSG (+33.65% | $5.65): Smashed Q1 earnings expectations with a 66% year-over-year revenue surge to $104.2 million and a swing to a $16.6 million adjusted net profit. $SITM (+33.48% | $835.00): Delivered a massive Q1 revenue beat with 88% year-over-year growth driven by AI infrastructure demand and raised its full-year revenue growth expectation to at least 80%. $DDOG (+29.37% | $186.00): Crushed Q1 earnings estimates with 32% year-over-year revenue growth and raised its full-year guidance amid strong AI and government platform momentum. $CCRN (+28.78% | $13.03): Entered into a definitive agreement to be acquired by private equity firm Knox Lane in an all-cash transaction valued at $13.25 per share. $HIMX (+28.39% | $15.86): Beat Q1 earnings estimates, provided strong Q2 guidance driven by automotive and AI growth, and declared an annual cash dividend representing a 100% payout of last year's profit. $AAON (+26.65% | $125.00): Reported record Q1 net sales up 54.3% year-over-year, driven by surging data center cooling demand, and raised its full-year revenue growth guidance to 40-45%. $RMSG (+26.51% | $1.67): Regained compliance with Nasdaq's minimum bid price requirement, removing the overhang of a potential delisting. $ASBP (+26.02% | $0.2345): Experiencing retail-driven momentum and a delayed reaction to a recently announced $5 million share repurchase program. $SABR (+24.61% | $2.29): Beat Q1 earnings estimates with an 8% year-over-year revenue increase and reaffirmed its full-year guidance amid a gradual recovery in air bookings. $SNES (+23.13% | $1.80): Gaining retail momentum as a sympathy play on a recent hantavirus outbreak due to its humane rat birth control product, ahead of anticipated Q1 earnings. $PCT (+22.70% | $9.42): Reported record Q1 production, its fifth straight quarter of sequential revenue growth, and final commercialization approvals for two Procter & Gamble applications. $RXT (+21.81% | $2.77): Surged on a Q1 earnings beat and the announcement of a strategic AI infrastructure collaboration with AMD to establish a governed Enterprise AI Cloud.
English
0
0
2
591
AskEdgar
AskEdgar@AskEdgarIO·
$AREB
AskEdgar tweet media
GIF
QME
0
0
1
889
AskEdgar
AskEdgar@AskEdgarIO·
I gave Claude Code access to AskEdgar. 60 seconds later it built a live pump-and-dump dashboard scanning every small-cap on the market. New video showing exactly how (link below):
English
1
1
4
1.5K
AskEdgar
AskEdgar@AskEdgarIO·
Premarket Movers: (Small caps likely will continue to see little action until earnings season wraps up - Semis up from $AMD +19.9% and $SMCI +15.0% - also $ARM +11.9% $MU +5.4% $INTC +6.0% $QCOM +5.9%) $EVC (+76.90% | $7.06): Shares are surging following a massive Q1 earnings beat where its Advertising Technology & Services segment revenue exploded 204% year-over-year, returning the company to profitability. $AVTX (+50.94% | $24.66): The stock is continuing its massive run after announcing positive Phase 2 LOTUS trial results for its hidradenitis suppurativa drug yesterday and pricing a $375 million public offering at a premium today. $GCTK (+46.55% | $1.07): Traders are driving up this low-float microcap on momentum and short-squeeze dynamics ahead of an anticipated Q2 FDA IDE filing for its implantable continuous glucose monitor, though no new catalyst was reported today. $EZGO (+46.32% | $2.78): This low-float Chinese micro-cap is experiencing extreme algorithmic momentum and sector rotation, though no recent company-specific news or catalyst was found. $SLP (+36.70% | $21.48): Shares spiked today after the company announced a technical collaboration with NVIDIA to integrate GPU-accelerated AI workflows into its pharmacological simulation software. $COMP (+33.47% | $9.69): Shares are rallying after a strong Q1 earnings beat and raised guidance that highlighted $200 million in realized synergies from its Anywhere Real Estate acquisition. $AHMA (+28.18% | $1.42): This low-float microcap is experiencing a delayed momentum squeeze following the filing of its 2025 Annual Report last week, though no fresh news was released today. $HUT (+27.52% | $102.99): The company reported Q1 earnings today and announced a massive 15-year, 352 MW AI data center lease at its Beacon Point campus with a base value of $9.8 billion. $FLEX (+22.58% | $119.32): Shares jumped today after the company delivered a Q4 earnings beat and announced a tax-free spin-off of its Cloud and Power Infrastructure segment into a new public company.
English
0
0
0
527
AskEdgar
AskEdgar@AskEdgarIO·
Premarket Movers: Here is your daily stock digest for May 5, 2026: $SDOT (+82.31% | $0.47): Surging on retail momentum and short squeeze speculation following its recent regain of Nasdaq compliance and ahead of its upcoming May 7 earnings report. $DGXX (+68.86% | $6.67): Skyrocketing after announcing a transformative 10-year, $1.1 billion AI colocation agreement with Cerebras Systems for a 40 MW data center campus in Alabama. $FSEA (+41.57% | $16.68): Surging after entering into a definitive merger agreement to be acquired by Cambridge Financial Group for $17.25 per share in cash. $BLZE (+40.95% | $6.58): Rallied on a strong Q1 earnings beat driven by 76% year-over-year growth in AI customers and raised full-year 2026 revenue and EBITDA guidance. $MASK (+37.59% | $2.00): Experiencing a technical, low-float momentum breakout following the recent announcement of a $1.3 million senior secured convertible note financing. $CLRB (+37.46% | $3.90): Spiked after reporting highly positive 12-month follow-up data from its Phase 2b trial for iopofosine I 131 and securing an oversubscribed financing round of up to $140 million. $BIYA (+31.93% | $1.58): Continuing to experience extreme low-float volatility and momentum trading following its recent "Ark Plan" crypto strategy announcement and reverse split. $STRL (+27.10% | $676.98): Jumped after reporting record Q1 results with a 92% year-over-year revenue increase and raising its full-year 2026 guidance. $VRDN (+24.89% | $17.63): Gained after announcing positive topline results from its Phase 3 REVEAL-2 trial for elegrobart in chronic thyroid eye disease, meeting all primary and key secondary endpoints. $CYTK (+23.39% | $81.50): Surged after announcing its Phase 3 ACACIA-HCM trial for aficamten met both dual primary endpoints with high statistical significance, expanding its potential market.
English
0
0
1
734
AskEdgar
AskEdgar@AskEdgarIO·
One of our API users built a full dilution monitor. Top gainers feed → research report → risk + offering breakdown, side by side. Wild what you can ship in a day or two with the right data underneath.
AskEdgar tweet mediaAskEdgar tweet media
AskEdgar@AskEdgarIO

x.com/i/article/2046…

English
1
1
6
1.1K
AskEdgar
AskEdgar@AskEdgarIO·
Here is your daily stock digest for May 4, 2026: $CNSP (+270.82% | $8.57): Shares are surging on heavy momentum trading following the announcement of a $22.5 million PIPE (with ADAR1 @Biohazard3737, Stonepine, Ikarian Capital and Nazare Partners) and a strategic pivot to acquire new clinical-stage assets. $PN (+78.71% | $5.13): The stock is seeing continued momentum from Friday's announcement of a $20.2 million acquisition to fully own Nanjing Cesun Power Co. alongside a $3 million private placement. $GBTG (+56.83% | $9.31): Shares are trading near the buyout price after the company announced a definitive agreement to be acquired by Long Lake Management for $9.50 per share in cash. $RLYB (+44.85% | $13.66): The company announced the termination of its merger with Candid Therapeutics, entitling Rallybio to a massive $50 million non-dilutive cash termination fee. $CLNN (+37.79% | $8.48): The company announced a successful FDA meeting that supports filing a New Drug Application under the accelerated approval pathway for its ALS drug candidate, CNM-Au8. $NIVF (+26.90% | $2.26): The company reported strong fiscal 2025 results featuring a $9.9 million net profit driven by a bargain purchase gain from recent intellectual property acquisitions. $ADVB (+25.24% | $6.61): Shares are continuing their low-float momentum run following Friday's announcement of a strategic pivot to AI and the acquisition of Acellent Technologies. $XHLD (+22.95% | $1.50): No recent news or catalysts were found to explain today's price action. $REKR (+22.47% | $1.07): The company secured a new multi-year, $16.8 million contract to continue providing its AI-enabled vehicle recognition technology for Oklahoma's uninsured motorist program. $BZAI (+20.17% | $2.44): The stock is rallying on a new strategic partnership with Winmate to integrate its edge AI chips into rugged hardware, targeting $15 million in first-year business.
English
0
0
6
760
AskEdgar
AskEdgar@AskEdgarIO·
"Same underwriter. Same entities holding warrants. Same chart structure developing." that's the whole framework, and the screeners are built around exactly this. great breakdown. full video below.
Dogtor🎰📈@Dogtor01416800

🧐Dilution was HARD, until I realized this...🧐 Most traders overcomplicate dilution. They get buried in exercise prices, price protection clauses, share calculations, and end up paralyzed by details that don't actually help them make better decisions. Here's the thing - you don't need to understand every mechanic. You need to find the common denominator. Same underwriter. Same entities holding warrants. Same chart structure developing. If you've seen how it played out before, you already have your thesis. 🎮 The Core Idea Stop trying to master every clause in every filing. Instead, ask three questions: Who's involved❓ the underwriter, the equity line provider, the warrant holders, the convertible note holders. How did it play out last time they were involved❓ Is the chart developing the same way❓ If the answer to all three points in the same direction, the odds favor a similar outcome. It won't always resolve identically - but from experience, it resolves similarly far more often than not. 🎮 Example 1 — $AHMA and the underwriter pattern When you pull up AHMA's dilution profile, it's almost blank. The only thing visible is an IPO underwritten by AC Sunshine. Not much to work with on its own. So the next step is to pull up the deal screener on askedgar.io, search AC Sunshine 🏦, and look at every other ticker they've been involved with. Go through the charts. See how those plays resolved. In this case, two tickers stood out - $CTNT and $TWWG . Both had the same setup: a high-volume trappy day one, followed by a slow grind upward over several days, then a full liquidation. When AHMA started developing the same pattern - trappy open, slow drift up, the thesis wrote itself. And it resolved the same way. You don't need to know exactly why it happened. Early lockup expiration, insider dumping, a third party accumulating and unloading - the specific mechanism doesn't matter. What matters is recognizing that the same people produced the same chart structure and the same outcome, and acting accordingly. 🎮 Example 2 — $MLEC and the equity line This one is different because the comparison isn't across tickers - it's the same ticker at different points in time. MLEC had an active equity line with an entity called Numera. Back in April 2024, they used it and the stock gapped and faded on the same day. Fast forward to a more recent move: pre-market action is developing almost identically. Similar gap, similar price action, same equity line still active. The one variable that was different this time was news. The April move had zero catalyst. The recent move had a news item - nothing with real fundamental impact, but enough to cause the gap. That may have made the setup slightly more resilient. Or maybe they didn't sell from the equity line this time. Or maybe outside players stayed away because the dilution overhang made the stock harder to control. The honest answer is: we don't know exactly. And that's fine. We don't need to know. Same entity, same structure, same developing chart — that's enough to build a thesis and manage around it. *The video this is based on is from the @AskEdgarIO YouTube channel. If you trade small caps and you're not watching it, you're missing the kind of structural knowledge that separates traders who understand what they're holding from those who find out the hard way: @askedgar" target="_blank" rel="nofollow noopener">youtube.com/@askedgar 💯 The Bottom Line Whether it's a registered offering, an equity line, a convertible note, or a straight secondary - the structure matters less than the pattern. Find the common denominator. Look at how the same people performed in previous setups. See if the chart is telling the same story. That's it. That's the whole framework. The traders who overcomplicate this are the ones who miss the move entirely while they're still reading footnotes. 🫂Where to do this research 🫂 Everything covered here - underwriter history, equity line providers, warrant holders, offering timelines, chart comparisons is searchable through askedgar.io. The deal screener alone is worth it: type in an underwriter or fund and pull up every ticker they've touched, along with what happened around each offering. For real-time tracking of shelves, equity lines, offering history, and filing alerts, here's my referral link. Transparent as always: small credit if you sign up, wouldn't share it if I wasn't using it myself: t.co/rwC54YhLqY 😋

English
0
3
9
2.9K
AskEdgar
AskEdgar@AskEdgarIO·
What are you building this weekend? Looks like epic dashboards. Dilution-rating, pump-and-dump tracker, and float are doing the heavy lifting.
AskEdgar tweet mediaAskEdgar tweet media
English
1
0
4
823
AskEdgar
AskEdgar@AskEdgarIO·
Here is your daily stock digest for May 1, 2026: $CUE (+94.42% | $28.75): Surged on a trifecta of news including a $30 million PIPE financing, an exclusive global license agreement for a Phase 2 anti-IgE antibody, and the appointment of a new CEO. $ESPR (+57.50% | $3.15): Announced it will be acquired by ARCHIMED for $3.16 per share in cash (a 58% premium) plus up to $100 million in contingent value rights tied to future drug sales. $SOBR (+53.99% | $0.84): Pivoting to the AI data center power space after announcing a proposed business combination with zero-carbon green energy tech company Clean World Ventures. $LABT (+35.71% | $3.61): Released positive antimicrobial resistance data for its lead compound Nu-3 targeting infected diabetic foot ulcers, fueling a low-float momentum rally. $AKAN (+29.74% | $63.59): Continuing an explosive multi-day short squeeze driven by a recent reverse split, an ultra-low float, and sector tailwinds from U.S. cannabis rescheduling news. $XXII (+23.08% | $1.93): Experiencing a low-float technical bounce following a recent 1-for-23 reverse stock split and the announcement of an ambitious 2026 growth strategy for its reduced-nicotine products. $TWLO (+22.13% | $181.00): Delivered a strong Q1 earnings beat, raised full-year 2026 guidance, and highlighted surging demand for its AI-related infrastructure.
English
0
0
2
809